WallStSmart

Alibaba Group Holding Ltd (BABA)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alibaba Group Holding Ltd generates 4965% more annual revenue ($1.02T vs $20.07B). BSX leads profitability with a 14.4% profit margin vs 8.9%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).

BABA

Hold

49

out of 100

Grade: D+

Growth: 4.0Profit: 6.0Value: 7.3Quality: 5.8
Piotroski: 5/9Altman Z: 2.39

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BABASignificantly Overvalued (-298.4%)

Margin of Safety

-298.4%

Fair Value

$38.22

Current Price

$129.87

$91.65 premium

UndervaluedFair: $38.22Overvalued
BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BABA3 strengths · Avg: 9.3/10
Market CapQuality
$299.57B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$36.03B10/10

Generating 36.0B in free cash flow

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

Areas to Watch

BABA3 concerns · Avg: 3.3/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

Revenue GrowthGrowth
1.7%4/10

1.7% revenue growth

EPS GrowthGrowth
-70.9%2/10

Earnings declined 70.9%

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : BABA

The strongest argument for BABA centers on Market Cap, Free Cash Flow, Price/Book.

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bear Case : BABA

The primary concerns for BABA are PEG Ratio, Revenue Growth, EPS Growth.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Key Dynamics to Monitor

BABA profiles as a value stock while BSX is a growth play — different risk/reward profiles.

BSX carries more volatility with a beta of 0.70 — expect wider price swings.

BSX is growing revenue faster at 15.9% — sustainability is the question.

BABA generates stronger free cash flow (36.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 49/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alibaba Group Holding Ltd

CONSUMER CYCLICAL · INTERNET RETAIL · USA

Alibaba Group Holding Limited, also known as Alibaba Group and Alibaba.com, is a Chinese multinational technology company specializing in e-commerce, retail, Internet, and technology. Founded on 28 June 1999 in Hangzhou, Zhejiang, the company provides consumer-to-consumer (C2C), business-to-consumer (B2C), and business-to-business (B2B) sales services via web portals, as well as electronic payment services, shopping search engines and cloud computing services. It owns and operates a diverse portfolio of companies around the world in numerous business sectors.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?